Effect of High-Dose vs Standard-Dose Vitamin D$_3$ Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial

Justin C. Brown$^{1,2,3,*}$, Michael H. Rosenthal$^{4,5}$, Chao Ma$^4$, Sui Zhang$^4$, Halla S. Nimeiri$^5$, Nadine J. McCleary$^4$, Thomas A. Abrams$^4$, Matthew B. Yurgelun$^4$, James M. Cleary$^4$, Douglas A. Rubinson$^{4,5}$, Deborah Schrag$^4$, Andrea A. Bullock$^6$, Jill Allen$^7$, Dan Zuckerman$^8$, Emily Chan$^9$, Jennifer A. Chan$^4$, Brian Wolpin$^4$, Michael Constantine$^{10}$, Douglas J. Weckstein$^{11}$, Meredith A. Faggen$^{12}$, Christian A. Thomas$^{13,5}$, Chryssanthi Kournioti$^{14,5}$, Chen Yuan$^4$, Hui Zheng$^7$, Bruce W. Hollis$^{15}$, Charles S. Fuchs$^{16}$, Kimmie Ng$^{4,5,†}$ and Jeffrey A. Meyerhardt$^{4,†}$

1 Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
2 LSU Health Sciences Center, New Orleans School of Medicine, New Orleans, LA 70012, USA
3 Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70012, USA
4 Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA; michael_rosenthal@dfci.harvard.edu (M.H.R.); Chao_Ma@DFCI.HARVARD.EDU (C.M.); suzi_zhang@jh.edu (S.Z.); NJ_McCleary@DFCI.HARVARD.EDU (N.J.M.); Thomas_Abrams@DFCI.HARVARD.EDU (T.A.A.); Matthew_Yurgelun@dfci.harvard.edu (M.B.Y.); JCLEARY@PARTNERS.ORG (J.M.C.); douglas_rubinson@dfci.harvard.edu (D.A.R.); Deb_Schrag@dfci.harvard.edu (D.S.); JANH@PARTNERS.ORG (J.A.C.); Brian_Wolpin@dfci.harvard.edu (B.W.); chen_yuan@dfci.harvard.edu (C.Y.); kimmie_ng@dfci.harvard.edu (K.N.); Jeffrey_Meyerhardt@dfci.harvard.edu (J.A.M.)
5 Division of Hematology Oncology, Department of Medicine, Northwestern University, Chicago, IL 60611, USA; hnimeiri@nm.org
6 Beth Israel Deaconess Medical Center, Boston, MA 02215, USA; abullock@bidmc.harvard.edu
7 Massachusetts General Hospital, Boston, MA 02114, USA; jallen0@partners.org (J.A.); hzheng1@partners.org (H.I.)
8 St Luke’s Mountain States Tumor Institute, Boise, ID 83712, USA; zuckermd@slhs.org
9 Vanderbilt University Medical Center, Nashville, TN 37232, USA; emyychan@yahoo.com
10 Dana-Farber at Milford Regional Medical Center, Milford, MA 01757, USA; Michael_Constantine@DFCI.HARVARD.EDU
11 New Hampshire Oncology Hematology, Hookset, NH 03106, USA; D.Weckstein@nhoh.com
12 Dana-Farber at South Shore Hospital, South Weymouth, MA 02190, USA; MEREDITH_FAGGEN@DFCI.HARVARD.EDU
13 New England Cancer Specialists,Scarborough, ME 04074, USA; thomac@neweecs.org
14 Newton-Wellesley Hospital, Newton, MA 02462, USA; CKOURNIOTI@PARTNERS.ORG
15 Department of Pediatrics, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA; holissb@musc.edu
16 Yale Cancer Center, New Haven, CT 06510, USA; charles.fuchs@yale.edu
* Correspondence: Justin.Brown@pbrc.edu; Tel.: +1-225-763-2715
† These authors contributed equally to this paper.

Received: 17 October 2020; Accepted: 6 November 2020; Published: 20 November 2020

Simple Summary: Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. It is unknown if high-dose vitamin D$_3$ impacts skeletal muscle and adipose tissue, as compared with standard-dose vitamin D$_3$, in patients with advanced or metastatic colorectal cancer. In this
exploratory analysis of a phase II randomized trial, high-dose vitamin D$_3$ did not lead to changes of body weight, body mass index, muscle area, muscle attenuation, visceral adipose tissue area, or subcutaneous adipose tissue area, as compared with standard-dose vitamin D$_3$. High-dose vitamin D$_3$ did not change body composition in patients receiving chemotherapy for advanced or metastatic colorectal cancer.

**Abstract:** Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. In this exploratory analysis of a double-blind, multicenter, randomized phase II clinical trial, 105 patients with advanced or metastatic colorectal cancer who were receiving chemotherapy were randomized to either high-dose vitamin D$_3$ (4000 IU) or standard-dose (400 IU) vitamin D$_3$. Body composition was measured with abdominal computed tomography at enrollment (baseline) and after cycle 8 of chemotherapy (16 weeks). As compared with standard-dose vitamin D$_3$, high-dose vitamin D$_3$ did not significantly change body weight $[-0.7 \text{ kg}; (95\% \text{ CI}: -3.5, 2.0)]$, body mass index $[-0.2 \text{ kg/m}^2; (95\% \text{ CI}: -1.2, 0.7)]$, muscle area $[-1.7 \text{ cm}^2; (95\% \text{ CI}: -9.6, 6.3)]$, muscle attenuation $[-0.4 \text{ HU}; (95\% \text{ CI}: -4.2, 3.2)]$, visceral adipose tissue area $[-7.5 \text{ cm}^2; (95\% \text{ CI}: -24.5, 9.6)]$, or subcutaneous adipose tissue area $[-8.3 \text{ cm}^2; (95\% \text{ CI}: -35.5, 18.9)]$ over the first 8 cycles of chemotherapy. Among patients with advanced or metastatic colorectal cancer, the addition of high-dose vitamin D$_3$, vs standard-dose vitamin D$_3$, to standard chemotherapy did not result in any changes in body composition.

**Keywords:** adipose tissue; colorectal neoplasms; cholecalciferol; mediation; prognosis; randomized; skeletal muscle

1. Introduction

More than 80% of the U.S. population has vitamin D insufficiency (e.g., 25-hydroxyvitamin D [25(OH)D] concentrations $\leq 30 \text{ ng/mL}$) [1]. Observational studies report that vitamin D insufficiency is independently associated with a higher risk of cancer death [2,3]. Meta-analyses of randomized controlled trials demonstrate that vitamin D supplementation reduces cancer death [4,5]. However, the mechanisms through which vitamin D supplementation may slow cancer progression and reduce cancer death are incompletely understood [6,7].

Skeletal muscle and adipose tissue express the vitamin D receptor [8–11]. In skeletal muscle, binding of the vitamin D receptor stimulates protein synthesis, resulting in muscle cell proliferation and growth [12,13]. Detailed reviews of these biological relationships have been reviewed elsewhere [14,15]. In adipose tissue, vitamin D and its receptor have been implicated in adipogenesis, lipid mobilization and utilization, and adipokine secretion [16,17]. This is relevant because measures of skeletal muscle and adipose tissue are prognostic of cancer progression and death in patients with various types of malignancies [18]. It is not known if the effects of vitamin D supplementation to slow cancer progression and reduce cancer death are mediated, in part, by changes in skeletal muscle and adipose tissue.

These observations provided the scientific rationale to conduct an exploratory analysis using data from the SUNSHINE trial. The SUNSHINE trial was a phase II randomized clinical trial that established the safety and preliminary efficacy of oral supplementation with high-dose vitamin D$_3$ (4,000 IU) as compared with standard-dose (400 IU) vitamin D$_3$ on progression-free survival in patients with advanced or metastatic colorectal cancer [19]. We hypothesized that high-dose vitamin D$_3$ would increase skeletal muscle and reduce adipose tissue, as compared with standard-dose vitamin D$_3$. Moreover, we hypothesized that the previously-reported improvement in progression-free survival with high-dose vitamin D$_3$ would be mediated by changes in skeletal muscle and adipose tissue [19].
2. Results

2.1. Baseline Participant Characteristics

Participant recruitment was conducted from 29 March 2012 and 9 November 2016. In total, 139 participants were randomized; 105 participants were evaluable in this exploratory analysis, which did not differ between groups \( (p = 0.32) \); the most common reason participants were not included in this analysis was because the obtained computed tomography image needed to quantify body composition was of insufficient quality or did not include the abdominal region (Figure 1). The 105 participants included in this exploratory analysis were significantly \( (p < 0.001) \) more likely to have mutated (48.8% vs 23.5%) or unknown (8.6% vs 2.9%) KRAS status than the 34 participants that were not included in this analysis (Table S1). As of September 1, 2018, all participants had completed study assigned treatments. The median follow-up from randomization was 22.9 months (IQR: 11.8–34.5 months). During follow-up, we observed 86 progression-free survival events and 77 overall survival events.

Baseline participant and tumor characteristics were balanced between the treatment groups (Table 1). The 75 participants in this analysis that had both, baseline and follow-up, body composition measures did not differ on any measured baseline characteristics than the 33 participants who only had one body composition measure (Table S2). Adherence to vitamin D3 was high, with a median of 98% of expected capsules taken by participants in both treatment groups. As compared with participants assigned to standard-dose vitamin D3, those assigned to high-dose vitamin D3 had significantly increased concentrations of plasma 25(OH)D over the first 8 cycles of chemotherapy \([20.0 \text{ ng/mL}; (95\% \text{ CI: } 14.7, 25.2); p < 0.001]\) (Table S3).

![Figure 1. Flow of participants.](image)

**Table 1.** Baseline characteristics of sub-study participants by randomized group.

| Characteristic     | High-Dose Vitamin D3 \((n = 50)\) | Standard-Dose Vitamin D3 \((n = 55)\) |
|-------------------|----------------------------------|-------------------------------------|
| Age, median (IQR), y | 54.2 (46.8–65.3) | 55.5 (49.2–64.7) |
| Sex, No. (%)       |                                  |                                     |
| Male               | 32 (64.0)                        | 27 (49.1)                           |
| Female             | 18 (36.0)                        | 28 (50.9)                           |
Table 1. Cont.

| Characteristic                        | High-Dose Vitamin D₃ (n = 50) | Standard-Dose Vitamin D₃ (n = 55) |
|---------------------------------------|-------------------------------|-----------------------------------|
| Race, Ethnicity, No. (%)              |                               |                                   |
| White                                 | 38 (76.0)                     | 43 (78.2)                         |
| Black                                 | 2 (4.0)                       | 5 (9.1)                           |
| Asian                                 | 0 (0)                         | 0 (0)                             |
| >1 Race                               | 0 (0.0)                       | 1 (1.8)                           |
| Other                                 | 10 (20.0)                     | 6 (10.9)                          |
| ECOG Performance Status, No. (%)      |                               |                                   |
| 0                                     | 21 (42.0)                     | 32 (58.2)                         |
| 1                                     | 29 (58.0)                     | 23 (41.8)                         |
| Primary Tumor Location, No. (%)       |                               |                                   |
| Right Colon                           | 12 (24.0)                     | 15 (27.3)                         |
| Transverse Colon                      | 3 (6.0)                       | 7 (12.7)                          |
| Left Colon, Rectum                    | 35 (70.0)                     | 33 (60.0)                         |
| Primary Tumor Resected, No. (%)       | 20 (40.0)                     | 17 (30.9)                         |
| No. of Metastatic Sites, mean (SD)    | 2.0 (0.93)                    | 1.9 (0.91)                        |
| Carcinoembryonic Antigen *, median (IQR), ng/mL | 64.8 (4.5–565.6) | 91.9 (5.5–393.5) |
| Microsatellite Instability Status, No. (%) |                               |                                   |
| High                                  | 1 (2.0)                       | 4 (7.3)                           |
| Stable                                | 42 (84.0)                     | 35 (63.6)                         |
| Unknown                               | 7 (14.0)                      | 16 (29.1)                         |
| KRAS Mutation Status, No. (%)         |                               |                                   |
| Wild Type                             | 26 (52.0)                     | 24 (43.6)                         |
| Mutated                               | 22 (44.0)                     | 24 (43.6)                         |
| Unknown                               | 2 (4.0)                       | 7 (12.7)                          |
| NRAS Mutation Status, No. (%)         |                               |                                   |
| Wild Type                             | 29 (58.0)                     | 30 (54.5)                         |
| Mutated                               | 0 (0.0)                       | 2 (3.6)                           |
| Unknown                               | 21 (42.0)                     | 23 (41.8)                         |
| BRAF V600E Mutation Status, No. (%)   |                               |                                   |
| Wild Type                             | 31 (62.0)                     | 30 (54.5)                         |
| Mutated                               | 3 (6.0)                       | 7 (12.7)                          |
| Unknown                               | 16 (32.0)                     | 18 (32.7)                         |

* Missing for 1 participant.

2.2. Effects of Intervention on Body Composition Outcome Measures

As compared with participants assigned to standard-dose vitamin D₃, those assigned to high-dose vitamin D₃ supplementation did not significantly change body weight [−0.7 kg; (95% CI: −3.5, 2.0); p = 0.61], body mass index [−0.2 kg/m²; (95% CI: −1.2, 0.7); p = 0.63], muscle area [−1.7 cm²; (95% CI: −9.6, 6.3); p = 0.68], muscle attenuation [−0.4 HU; (95% CI: −4.2, 3.2); p = 0.81], visceral adipose tissue area [−7.5 cm²; (95% CI: −24.5, 9.6); p = 0.39], or subcutaneous adipose tissue area [−8.3 cm²; (95% CI: −35.5, 18.9); p = 0.55] over the first 8 cycles of chemotherapy (Table 2). Results were similar in sensitivity analyses using maximum-likelihood regression without multiple imputation (Table S4). Nine participants experienced disease progression with the first 8 cycles of chemotherapy [2 (4.0%) in the high-dose vitamin D₃ group and 7 (12.7%) in the standard-dose vitamin D₃ group, p = 0.11]; results were similar after excluding these participants.
Table 2. Effects of vitamin D₃ supplementation on change in body composition outcomes using multiple imputation analysis.

| Outcome & Group | Baseline [LS Mean (SE)] | Follow-Up [LS Mean (SE)] | Δ Baseline to Follow-Up (LS Mean, 95% CI) | Δ Between Group (LS Mean, 95% CI) | p |
|-----------------|-------------------------|--------------------------|------------------------------------------|----------------------------------|---|
| Body Weight, kg | High-Dose Vitamin D₃     | 82.0 (3.1)               | 81.0 (3.3)                               | −1.0 (−2.9, 0.9)                  | −0.7 (−3.5, 2.0) | 0.61 |
|                 | Standard-Dose Vitamin D₃ | 76.8 (3.2)               | 76.5 (3.4)                               | −0.3 (−2.3, 1.7)                  |          |    |
| Body Mass Index, kg/m² | High-Dose Vitamin D₃   | 28.7 (0.99)              | 28.4 (1.03)                              | −0.3 (−1.0, 0.3)                  | −0.2 (−1.2, 0.7) | 0.63 |
|                 | Standard-Dose Vitamin D₃ | 27.2 (1.03)              | 27.1 (1.07)                              | −0.1 (−0.8, 0.6)                  |          |    |
| Muscle Area, cm² | High-Dose Vitamin D₃     | 139.3 (4.6)              | 135.4 (4.9)                              | −3.9 (−8.8, 1.0)                  | −1.7 (−9.6, 6.3) | 0.68 |
|                 | Standard-Dose Vitamin D₃ | 133.5 (4.8)              | 131.3 (5.3)                              | −2.3 (−7.9, 3.4)                  |          |    |
| Muscle Attenuation, HU | High-Dose Vitamin D₃   | 34.9 (1.47)              | 35.0 (1.74)                              | 0.1 (−2.4, 2.6)                   | −0.4 (−4.2, 3.2) | 0.81 |
|                 | Standard-Dose Vitamin D₃ | 38.0 (1.52)              | 38.6 (1.73)                              | 0.6 (−2.2, 3.4)                   |          |    |
| Visceral Adipose Tissue Area, cm² | High-Dose Vitamin D₃   | 130.8 (15.3)             | 128.0 (15.3)                             | −2.8 (−14.7, 9.2)                 | −7.5 (−24.5, 9.6) | 0.39 |
|                 | Standard-Dose Vitamin D₃ | 111.5 (15.8)             | 116.1 (16.0)                             | 4.7 (−7.9, 17.3)                  |          |    |
| Subcutaneous Adipose Tissue Area, cm² | High-Dose Vitamin D₃   | 230.5 (20.1)             | 226.0 (22.1)                             | −4.5 (−24, 15.1)                  | −8.3 (−35.5, 18.9) | 0.55 |
|                 | Standard-Dose Vitamin D₃ | 207.6 (20.6)             | 211.5 (22.6)                             | 3.8 (−15.2, 22.9)                 |          |    |

All results were from a regression model for repeated measurements that was adjusted for age, number of metastatic sites, sex, race, and ECOG performance status.
2.3. Correlation between Change in Plasma 25(OH)D and Body Composition

Among all participants, change in plasma 25(OH)D concentration from baseline to cycle 8 was not significantly associated with change in body weight \([r = -0.24; (95\% \text{ CI}: -0.46, 0.01); p = 0.054]\), body mass index \([r = -0.23; (95\% \text{ CI}: -0.45, 0.02); p = 0.067]\), muscle area \([r = -0.17; (95\% \text{ CI}: -0.41, 0.09); p = 0.19]\), muscle attenuation \([r = 0.16; (95\% \text{ CI}: -0.10, 0.41); p = 0.21]\), visceral adipose tissue area \([r = -0.05; (95\% \text{ CI}: -0.30, 0.21); p = 0.71]\), and subcutaneous adipose tissue area \([r = 0.01; (95\% \text{ CI}: -0.26, 0.26); p = 0.99]\).

2.4. Mediation Effect of Body Composition on Vitamin D₃ and Progression-Free Survival

In the subgroup of 105 participants included this exploratory analysis, randomization to high-dose vitamin D₃ was associated with a lower risk of disease progression or death as compared with low-dose vitamin D₃ \([HR: 0.67; (95\% \text{ CI}: 0.42, 1.07)]; \) the magnitude of risk reduction was similar to that observed in the full analysis set of 139 participants as previously reported \([HR: 0.64; (95\% \text{ CI}: 0.0–0.90)] [19]\). Change in body weight \([HR: 0.69; (95\% \text{ CI}: 0.40, 1.18)]; \) body mass index \([HR: 0.69; (95\% \text{ CI}: 0.40, 1.17)]; \) muscle area \([HR: 0.62; (95\% \text{ CI}: 0.35, 1.11)]; \) muscle attenuation \([HR: 0.73; (95\% \text{ CI}: 0.42, 1.25)]; \) visceral adipose tissue area \([HR: 0.77; (95\% \text{ CI}: 0.44, 1.36)]; \) and subcutaneous adipose tissue area \([HR: 0.76; (95\% \text{ CI}: 0.44, 1.33)]; \) over the first 8 cycles of chemotherapy did not mediate the association between randomized group and progression-free survival (Table 3).

Table 3. Change in effect of vitamin D₃ supplementation randomized group on progression-free survival before and after adjustment for change in body composition.

| Before Adjustment | Hypothesized Mediator | After Adjustment |
|-------------------|-----------------------|-----------------|
| Hazard Ratio (95% CI) |                        | Hazard Ratio (95% CI) |
| 0.67 (0.42, 1.07) | ∆ Body Weight          | 0.69 (0.40, 1.18) |
|                   | ∆ Body Mass Index      | 0.69 (0.40, 1.17) |
|                   | ∆ Muscle Area          | 0.62 (0.35, 1.11) |
|                   | ∆ Muscle Attenuation   | 0.73 (0.42, 1.25) |
|                   | ∆ Visceral Adipose Tissue Area | 0.77 (0.44, 1.36) |
|                   | ∆ Subcutaneous Adipose Tissue Area | 0.76 (0.44, 1.33) |

Hazard ratios compare high-dose vitamin D₃ supplementation with standard-dose vitamin D₃ supplementation and were estimated from a Cox proportional hazards model that was adjusted for age, number of metastatic sites, sex, race, and ECOG performance status.

2.5. Prognostic Effect of Body Composition on Progression-Free and Overall Survival

In restricted cubic spline analysis, no baseline body composition measures were significantly associated with progression-free survival (Figure S1); baseline muscle area (nonlinear \(p = 0.026\)) and visceral adipose tissue area (nonlinear \(p = 0.01\)) were significantly associated with overall survival (Figure S2). Change in muscle attenuation from baseline to cycle 8 (nonlinear \(p = 0.002\)) was significantly associated with progression-free survival (Figure S3); no change in body composition measures from baseline to cycle 8 were significantly associated with overall survival (Figure S4).

3. Discussion

In this exploratory analysis of a phase II trial, high-dose vitamin D₃ vs standard-dose vitamin D₃ did not significantly change skeletal muscle and adipose tissue among patients with metastatic colorectal cancer receiving standard chemotherapy. Among both randomized groups, change in plasma 25(OH)D concentration did not correlate with changes in body composition. Change in skeletal muscle and adipose tissues did not mediate the effect of high-dose vitamin D₃ on progression-free survival in this population. Among both randomized groups, baseline muscle area and visceral adipose tissue area were associated with overall survival and change in muscle attenuation from baseline to cycle 8 was associated with progression-free survival. These exploratory findings help to clarify the potential
mechanisms through which vitamin D supplementation may slow cancer progression and reduce cancer death.

At the time of diagnosis, ≥80% of patients with advanced or metastatic colorectal cancer have 25(OH)D concentrations ≤30 ng/mL [20]. A prospective analysis of 1043 patients with metastatic colorectal cancer who participated in a randomized phase III clinical trial of first-line chemotherapy plus biologic therapy demonstrated that patients with plasma 25(OH)D concentrations ≥20 ng/mL had a 19% reduced risk of disease progression [HR: 0.81; (95% CI: 0.66–1.00)] and a 30% reduced risk of death [HR: 0.70; (95% CI: 0.56–0.86)], as compared with plasma 25(OH)D concentrations <10 ng/mL [21]. A meta-analysis of 11 observational studies that included 7718 patients with stage I-IV colorectal cancer demonstrated that 25(OH)D was independently and inversely associated with cancer-specific and overall survival [22].

We hypothesized that one of the mechanisms by which vitamin D₃ supplementation exerts anticancer effects is through its impact on body composition. Our hypothesis was founded on the convergence of several lines of evidence. Skeletal muscle and adipose tissue express the vitamin D receptor [8–11]. In cross-sectional studies, concentrations of 25(OH)D positively correlate with skeletal muscle and negatively correlate with visceral and subcutaneous adipose tissue [23,24]. Skeletal muscle and adiposity are independent prognostic factors in patients with colorectal cancer [25–27]. The findings from this exploratory analysis, however, are not consistent with this hypothesis. Our observations support the results of several meta-analyses in various populations that vitamin D supplementation does not substantively change body composition [28–30].

There are several limitations to this trial. The main limitation is that this was an unplanned, exploratory, post hoc analysis and the findings, although null, should be interpreted conservatively. The relatively modest sample size may have limited our ability to detect small, but potentially clinically meaningful effects of vitamin D₃ supplementation on body composition outcomes. The current sample size provided sufficient statistical power to detect moderate to large treatment effects. The racially and geographically homogeneous sample also limited our ability to detect treatment effects in participant subgroups. The intervention duration was 16 weeks (8 cycles of mFOLFOX6 chemotherapy), which limits our ability to understand the benefits of vitamin D₃ supplementation on body composition over longer time horizons. The intervention did not include other supplements that may enhance the absorption of vitamin D, such as calcium, magnesium, and marine n-3 fatty acids. The study population was not recruited on the basis of having unfavorable body composition at baseline, which limits our understanding of treatment effect in patients with low muscle or excess adiposity at baseline.

There are several strengths to this trial. The randomized double-blind design allowed for a direct comparison of treatment effect of high-dose vitamin D₃ on body composition outcomes. Study participants were recruited from both academic and community-based cancer centers. Based on changes in plasma 25(OH)D concentrations, there was high supplement adherence, and no evidence of control group crossover, despite availability of vitamin D₃ supplements over the counter to patients. Body composition was ascertained using computed tomography, a gold-standard modality for muscle and adipose tissue measurement [31], by staff who were blinded to randomized group assignment.

4. Materials and Methods

4.1. Study Design

This study was a double-blind, multicenter, randomized phase II clinical trial. The study was conducted at 11 academic and community cancer centers across the United States. The study was conducted in accordance with Good Clinical Practice and the ethical principles originating in the Declaration of Helsinki. The protocol and informed consent document were approved by the institutional review board for each study site (coordinating center, Dana-Farber Cancer Institute, IRB Protocol 11-436; approved 12/27/2011). An independent data and safety monitoring board provided oversight of the study. All participants provided written informed consent prior to completing any study-related
activities. The study was registered on ClinicalTrials.gov as NCT01516216. The detailed study protocol is published [19].

4.2. Participants

Patients were eligible if they had pathologically confirmed, unresectable locally advanced or metastatic adenocarcinoma of the colon or rectum with measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 [32]. Patients were eligible if the last dose of prior chemotherapy or chemoradiotherapy was ≥12 months before study enrollment. Eligible patients had an Eastern Cooperative Group (ECOG) performance status of 0–1, with adequate organ function, and no evidence of hypercalcemia or conditions that may increase the risk of hypercalcemia (e.g., hyperparathyroidism). Patients were ineligible if they were taking ≥2000 IU daily of vitamin D₃, had symptomatic genitourinary stones within the past year, or were taking thiazide diuretics.

4.3. Randomization and Blinding

Participants were randomly assigned by the trial statistician in a 1:1 ratio to high-dose vitamin D₃ or standard-dose vitamin D₃ (described in detail below) using a computerized block randomization procedure with a block size of two. The trial statistician and research pharmacist were not blinded to treatment assignment. Study participants and treating physicians were blinded to treatment assignment.

4.4. Intervention

All study participants received chemotherapy with the mFOLFOX6 regimen, plus bevacizumab, administered every 2 weeks (1 cycle = 2 weeks) [33]. Bevacizumab could be omitted during cycle 1 and commenced with cycle 2, per treating physician discretion.

Vitamin D₃ capsules and placebos were identical in appearance (Pharmavite, LLC, West Hills, CA, USA). After randomization, participants were instructed to cease consumption of all supplements containing vitamin D and calcium outside of the study intervention. The high-dose vitamin D₃ group received an initial daily dose of 8000 IU of vitamin D₃ (two 4000 IU capsules) for cycle 1, and 4000 IU per day for all subsequent cycles. The standard-dose group received 400 IU daily during all cycles (one 400 IU capsule plus one placebo capsule during cycle 1 to maintain blinding). Adherence to vitamin D₃ was monitored using participant diaries and pill bottle reconciliation. Plasma 25(OH)D concentrations were quantified using a radioimmunoassay (DiaSorin, Inc., Saluggia, Italy). Participants continued to receive the study intervention until disease progression, intolerable toxicity, or decision to discontinue treatment.

4.5. Body Composition Outcome Measures

Height (meters) and weight (kilograms) were measured by trained medical assistants. Body mass index was calculated as kilograms of body weight per square meter of height (kg/m²). Body composition was measured using computed tomography (CT) images that were obtained with standard clinical contrast-enhanced protocols using slice-O-matic software (V4.3, TomoVision, Montreal, QC, Canada). A single slice transverse image at the third lumbar vertebra was used because tissue cross-sectional areas at this lumbar region are correlated with whole-body tissue volume [34,35]. Tissues were demarcated with a semiautomated procedure using Hounsfield Unit thresholds of −29 to 150 for muscle tissue (including all paraspinal and abdominal wall muscles), −150 to −50 for visceral adipose tissue, and −190 to −30 for subcutaneous adipose tissue. Cross-sectional areas were calculated for each tissue compartment by summing tissue pixels and multiplying by the pixel surface area. Muscle radiodensity quantified the average radiation attenuation rate as a radiologic measure of the extent of lipid contained within muscle [36]. Images were analyzed by trained staff who were blinded to study hypothesis, trial design, and image order (baseline vs. restaging follow-up). Coefficients of variation were 0.5% for muscle (individual reader range: 0.5–1.1%), 0.7% (0.4–1.0%) for visceral
adipose tissue area, and 0.4% (0.2–0.5%) for subcutaneous adipose area [37]. Final data verification was performed by a board-certified radiologist who was blinded to randomized group assignment (M.H.R.). Body composition was analyzed at baseline (pre-treatment) and at the second tumor restaging (cycle 8 of chemotherapy = 16 weeks of randomized study treatment).

4.6. Other Measures

Data for participant characteristics including age, sex, race and ethnicity, ECOG performance status, primary tumor location, primary tumor resection status, receipt of prior cancer-directed therapy, number of metastatic sites, carcinoembryonic antigen (CEA) concentration, and tumor mutational profile—including microsatellite instability, KRAS, NRAS, and BRAF V600E status—were obtained from a combination of participant self-report, physician assessment, and the medical record.

4.7. Statistical Analysis

The sample size was selected to provide sufficient statistical power to detect change in the primary endpoint of progression-free survival [19]. Measures of body composition were analyzed as exploratory study outcomes. Descriptive statistics presented for baseline variables include counts with proportions for categorical variables and medians with interquartile (25–75%) ranges for continuous variables. Categorical baseline characteristics were compared using the Fisher’s exact or χ² tests, and continuous baseline characteristics were compared using the Kruskal–Wallis or t-tests.

All analyses adhered to the modified intention-to-treat principle. The primary modeling strategy evaluated the treatment policy estimand (i.e., the treatment effect regardless of adherence or discontinuation) quantified using a generalized linear model for repeated measures with missing data imputed by a pattern mixture model with multiple imputation [38,39]. The secondary modeling strategy evaluated the trial product estimand (i.e., the treatment effect assuming all patients remained on trial) quantified using a mixed model for repeated measures with observed data (e.g., no imputation) [38]. The baseline value of the dependent variable was included as a covariate in the regression models [40]. Treatment effects were estimated as the group-by-time interaction with least-square means ± standard error or corresponding 95% confidence intervals. Model fit was assessed using graphical and numeric techniques. Sensitivity analyses excluded participants who experienced tumor progression within the first 8 cycles of chemotherapy. The Pearson correlation coefficient with bootstrapped 95% confidence intervals were used to quantify the strength of the association between change in plasma 25(OH)D and body composition [41].

The degree to which change in skeletal muscle and adipose tissue mediate the previously-reported treatment effect on progression-free survival was estimated using techniques for continuous mediators and time-to-event outcomes [42]. Additional analyses that consolidated the two randomized groups were conducted to quantify the association between body composition with progression-free survival and overall survival outcomes. Multivariable-adjusted Cox proportional hazards models were used to estimate hazard ratios and 95% CIs with restricted cubic splines [43]. Models were adjusted a priori for age, sex, race/ethnicity, ECOG performance status, and the number of metastatic sites [19]. The proportionality of hazards assumption was examined with visual inspection of log–log plots and tested in a regression model of the scaled Schoenfeld residuals on time [44].

5. Conclusions

Among patients with advanced or metastatic colorectal cancer, the addition of high-dose vitamin D₃, vs standard-dose vitamin D₃, to standard chemotherapy did not result in any differences in body composition. The findings from this exploratory study indicate that the benefits of vitamin D₃ on reducing cancer progression and death are unlikely to be mediated by changes in body composition. A multicenter, double-blind, randomized phase III trial is currently underway to evaluate the efficacy of high-dose vs. standard-dose vitamin D₃ on progression-free survival in 400 patients with metastatic colorectal cancer, and the correlative studies embedded into this trial will offer unprecedented insight into mechanisms of treatment benefit [45].
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/11/3451/s1,
Figure S1: Association of baseline body composition with progression-free survival (PFS), Figure S2: Association of baseline body composition with overall survival (OS), Figure S3: Association of change in body composition from baseline to follow-up with progression-free survival (PFS), Figure S4: Association of change in body composition from baseline to follow-up with overall survival (OS), Table S1: Comparison of baseline characteristics of sub-study participants compared to non-participants, Table S2: Comparison of baseline characteristics of sub-study participants with baseline and follow-up body composition measures compared to only baseline body composition measures, Table S3: Change in of vitamin D3 supplementation on plasma 25-hydroxyvitamin D concentrations among body composition sub-study participants, Table S4: Effects of vitamin D3 supplementation on change in body composition outcomes using maximum likelihood regression without multiple imputation.

Author Contributions: J.C.B., M.H.R., C.M., H.Z., K.N., and J.A.M. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: J.C.B.; C.M.; M.H.R.; S.Z.; H.S.N.; N.J.M.; T.A.A.; M.B.Y.; J.M.C.; D.A.R.; D.S.; A.J.B.; J.A.; D.Z.; E.C.; J.A.C.; B.W.; M.C.; D.J.W.; M.A.F.; C.A.T.; C.K.; C.Y.; H.Z.; B.W.H.; C.S.F.; K.N.; J.A.M. Drafting of the manuscript: J.C.B.; M.H.R.; C.M.; K.N.; J.A.M. Critical revision of the manuscript: S.Z.; H.S.N.; N.J.M.; T.A.A.; M.B.Y.; J.M.C.; D.A.R.; D.S.; A.J.B.; J.A.; D.Z.; E.C.; J.A.C.; B.W.; M.C.; D.J.W.; M.A.F.; C.A.T.; C.K.; C.Y.; H.Z.; B.W.H.; C.S.F. Statistical analysis: J.C.B.; C.M.; H.Z.; H.O. Obtained funding: J.C.B.; C.S.F., K.N., J.A.M. Administrative, technical, or material support: J.C.B.; C.M.; M.H.R.; S.Z.; H.S.N.; N.J.M.; T.A.A.; M.B.Y.; J.M.C.; D.A.R.; D.S.; A.J.B.; J.A.; D.Z.; E.C.; J.A.C.; B.W.; M.C.; D.J.W.; M.A.F.; C.A.T.; C.K.; C.Y.; H.Z.; B.W.H.; C.S.F.; K.N.; J.A.M. Supervision: J.C.B.; M.H.R.; H.S.N.; D.Z.; C.A.T.; C.S.F.; K.N.; J.A.M. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by grants R00-CA218603, R25-CA203650, P50CA127003, R01CA205406, R01CA118553 from the National Cancer Institute of the National Institutes of Health, grant U54-GM104940 from the National Institute of General Medicine Sciences of the National Institutes of Health, and grant P30-DK072476 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Additional funding was provided by the Gloria Spivak Faculty Advancement Award, Friends of Dana-Farber Cancer Institute Award, Project P Fund, Douglas Gray Woodruff Chair fund, Consano, Pharmavite LLC, and Genentech. Pharmavite provided the vitamin D3 and placebo capsules for the study. The funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation of the manuscript; and decision to submit the manuscript for publication. Pharmavite and Genentech reviewed and approved the manuscript.

Conflicts of Interest: J.C.B. reported receiving grants from the National Institutes of Health the American Institute for Cancer Research, and the Susan G. Komen Foundation. H.S.N. reported being employed at AbbVie. T.A.A. reported receiving grants from Eli Lilly and Bristol-Myers Squibb; and receiving personal fees from Bristol-Myers Squibb and Genentech. M.B.Y. reported consulting fees from Janssen Pharmaceuticals and receiving personal fees for peer review services from UpToDate. J.M.C. received research funding to his institution from Abbvie, Merus, Roche, and Bristol Myers Squibb; received research funding from Merck, Astrazeneca, Esparsa Pharma, and Tesaro; received consulting fees from Bristol Myers Squibb; and received travel funding from Bristol Myers Squibb. D.S. reported receiving personal fees from JAMA; receiving grants from Pfizer, the Alliance for Clinical Trials in Oncology, the American Association for Cancer Research, the National Cancer Institute, the Patient-Centered Outcomes Research Institute, and the American Cancer Society; and receiving nonfinancial support from Epic Systems Corporation. A.J.B. reported receiving personal fees from Taiho Oncology, Bayer, Eisai, Exelixis, and Celgene. E.C. reported being employed at Amgen; and receiving funding from Dana-Farber Cancer Institute and owning shares of Amgen stock. J.A.C. reported receiving personal fees from Novartis, Ipsen, Lexicon, AAA, and Exelixis; and receiving support from Novartis, Merck, Sanofi, and Lilly. B.W. reported receiving grants from Celgene; and receiving personal fees from BioLineRx and Grail. C.A.T. reported receiving personal fees from Genetech/Roche, Bristol-Myers Squibb, and Axtra Zeneca. H.Z. reported receiving grants from the National Institutes of Health. C.S.F. reported receiving personal fees from Eli Lilly, Entrisic Health, Pfizer, Merck, Sanofi, Roche, Genentech, Merrimack Pharma, Dicerna, Bayer, Celgene, Agios, Gilead Sciences, Five Prime Therapeutics, Taiho, KEW, and CytomX Therapeutics; and receiving support from CytomX Therapeutics. K.N. reported receiving grants from the National Cancer Institute, Genentech, Consano, Gilead Sciences, Tarrex Biopharma, Tvoragen, Celgene, and Pharmavite; and receiving personal fees from Genentech, Lilly, Tarrex Biopharma, Bayer, and Seattle Genetics. J.A.M. has received institutional research funding from Boston Biomedical, has served as an advisor/consultant to Ignyta and COTA Healthcare, and served on a grant review panel for the National Comprehensive Cancer Network funded by Taiho Pharmaceutical. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Schleicher, R.L.; Sternberg, M.R.; Lacher, D.A.; Sempos, C.T.; Looker, A.C.; Durazo-Arvizu, R.A.; Yetley, E.A.; Chaudhary-Webb, M.; Maw, K.L.; Pfeiffer, C.M.; et al. The vitamin D status of the US population from 1988 to 2010 using standardized serum concentrations of 25-hydroxyvitamin D shows recent modest increases. Am. J. Clin. Nutr. 2016, 104, 454–461. [CrossRef] [PubMed]
2. Theodoratou, E.; Tzoulaki, I.; Zgaga, L.; Ioannidis, J.P. Vitamin D and multiple health outcomes: Umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014, 348, g2035. [CrossRef] [PubMed]

3. Michaelsson, K.; Baron, J.A.; Snellman, G.; Gedeborg, R.; Byberg, L.; Sundstrom, J.; Berglund, L.; Arnlov, J.; Hellman, P.; Blomhoff, R.; et al. Plasma vitamin D and mortality in older men: A community-based prospective cohort study. Am. J. Clin. Nutr. 2010, 92, 841–848. [CrossRef] [PubMed]

4. Zhang, Y.; Fang, F.; Tang, J.; Jia, L.; Feng, Y.; Xu, P.; Faramand, A. Association between vitamin D supplementation and mortality: Systematic review and meta-analysis. BMJ 2019, 366, 14673. [CrossRef]

5. Keum, N.; Lee, D.H.; Greenwood, D.C.; Manson, J.E.; Giovannucci, E. Vitamin D supplementation and total cancer incidence and mortality: A meta-analysis of randomized controlled trials. Ann. Oncol. 2019, 30, 733–743. [CrossRef]

6. Feldman, D.; Krishnan, A.V.; Swami, S.; Giovannucci, E.; Feldman, B.J. The role of vitamin D in reducing cancer risk and progression. Nat. Rev. Cancer 2014, 14, 342–357. [CrossRef]

7. Bouillon, R.; Marcocci, C.; Carmeliet, G.; Bikle, D.; White, J.H.; Dawson-Hughes, B.; Lips, P.; Munns, C.F.; Lazaretti-Castro, M.; Giustina, A.; et al. Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions. Endocr. Rev. 2019, 40, 1109–1151. [CrossRef]

8. Costa, E.M.; Blau, H.M.; Feldman, D. 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology 1986, 119, 2214–2220. [CrossRef]

9. Blumberg, J.M.; Tzameli, I.; Astapova, I.; Lam, F.S.; Flier, J.S.; Hollenberg, A.N. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J. Biol. Chem. 2006, 281, 11205–11213. [CrossRef]

10. Bischoff, H.A.; Borchers, M.; Gadat, F.; Duermueller, U.; Theiler, R.; Stahelin, H.B.; Dick, W. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem. J. 2001, 33, 19–24. [CrossRef]

11. Nimitphong, H.; Holick, M.F.; Fried, S.K.; Lee, M.J. 25-hydroxyvitamin D(3) and 1,25-dihydroxyvitamin D(3) promote the differentiation of human subcutaneous preadipocytes. PLoS ONE 2012, 7, e52171. [CrossRef] [PubMed]

12. Domingues-Faria, C.; Boirie, Y.; Walrand, S. Vitamin D and muscle trophicity. Curr. Opin. Clin. Nutr. Metab. Care 2017, 20, 169–174. [CrossRef] [PubMed]

13. Ceglia, L. Vitamin D and its role in skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12, 628–633. [CrossRef] [PubMed]

14. Girgis, C.M.; Clifton-Bligh, R.J.; Hamrick, M.W.; Holick, M.F.; Gunton, J.E. The roles of vitamin D in skeletal muscle: Form, function, and metabolism. Endocr. Rev. 2013, 34, 33–83. [CrossRef] [PubMed]

15. Abbas, M.A. Physiological functions of Vitamin D in adipose tissue. J. Steroid Biochem. Mol. Biol. 2017, 165, 369–381. [CrossRef]

16. Ding, C.; Gao, D.; Wilding, J.; Trayhurn, P.; Bing, C. Vitamin D signalling in adipose tissue. Br. J. Nutr. 2012, 108, 1915–1923. [CrossRef]

17. Mutt, S.J.; Hypponen, E.; Saarnio, J.; Jarvelin, M.R.; Herzig, K.H. Vitamin D and adipose tissue-more than storage. Front. Physiol. 2014, 5, 228. [CrossRef]

18. Brown, J.C.; Cespedes Feliciano, E.M.; Caan, B.J. The evolution of body composition in oncology-epidemiology, clinical trials, and the future of patient care: Facts and numbers. J. Cachexia Sarcopenia Muscle 2018, 9, 1200–1208. [CrossRef]

19. Ng, K.; Nimeiri, H.S.; McLeary, T.A.; Abrams, T.A.; Yurgelun, M.B.; Cleary, J.M.; Rubinson, D.A.; Schrag, D.; Miksad, R.; Bullock, A.J.; et al. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA 2019, 321, 1370–1379. [CrossRef]

20. Ng, K.; Sargent, D.J.; Goldberg, R.M.; Meyerhardt, J.A.; Green, E.M.; Pitot, H.C.; Hollis, B.W.; Pollak, M.N.; Fuchs, C.S. Vitamin D status in patients with stage IV colorectal cancer: Findings from Intergroup trial N9741. J. Clin. Oncol. 2011, 29, 1599–1606. [CrossRef]

21. Yuan, C.; Sato, K.; Hollis, B.W.; Zhang, S.; Niedzwiecki, D.; Ou, F.S.; Chang, I.W.; O’Neil, B.H.; Innocenti, F.; Lenz, H.J.; et al. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clin. Cancer Res. 2019, 25, 7497–7505. [CrossRef] [PubMed]
Cancers 2020, 12, 3451

22. Maalmi, H.; Walter, V.; Jansen, L.; Boakye, D.; Schottker, B.; Hoffmeister, M.; Brenner, H. Association between Blood 25-Hydroxyvitamin D Levels and Survival in Colorectal Cancer Patients: An Updated Systematic Review and Meta-Analysis. *Nutrients* 2018, 10, 896. [CrossRef]

23. Visser, M.; Deeg, D.J.; Lips, P.; Longitudinal Aging Study Amsterdam. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The Longitudinal Aging Study Amsterdam. *J. Clin. Endocrinol. Metab.* 2003, 88, 5766–5772. [CrossRef] [PubMed]

24. Cheng, S.; Massaro, J.M.; Fox, C.S.; Larson, M.G.; Keyes, M.J.; McCabe, E.L.; Robins, S.J.; O’Donnell, C.J.; Hoffmann, U.; Jacques, P.F.; et al. Adiposity, cardiometabolic risk, and vitamin D status: The Framingham Heart Study. *Diabetes* 2010, 59, 242–248. [CrossRef] [PubMed]

25. Brown, J.C.; Caan, B.J.; Meyerhardt, J.A.; Weltzien, E.; Xiao, J.J.; Feliciano, E.M.C.; Kroenke, C.H.; Castillo, A.; Kwan, M.L.; Prado, C.M. The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: A population-based cohort study (C-SCANS). *J. Cachexia Sarcopenia Muscle* 2018, 9, 664–672. [CrossRef] [PubMed]

26. Brown, J.C.; Caan, B.J.; Prado, C.M.; Cespedes Feliciano, E.M.; Xiao, J.; Kroenke, C.H.; Meyerhardt, J.A. The Association of Abdominal Adiposity with Mortality in Patients With Stage I-III Colorectal Cancer. *J. Natl. Cancer Inst.* 2020, 112, 377–383. [CrossRef] [PubMed]

27. Blauwhoof-Buskermolen, S.; Versteeg, K.S.; de van der Schuern, M.A.; Den Braver, N.R.; Berkhof, J.; Langius, J.A.; Verheul, H.M. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. *J. Clin. Oncol.* 2016, 34, 1339–1344. [CrossRef] [PubMed]

28. Beaudart, C.; Bucinkx, F.; Rabenda, V.; Gillain, S.; Cavalier, E.; Slomian, J.; Petermans, J.; Reginster, J.Y.; Bruyere, O. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: A systematic review and meta-analysis of randomized controlled trials. *J. Clin. Endocrinol. Metab.* 2014, 99, 4336–4345. [CrossRef]

29. Golzarand, M.; Hollis, B.W.; Mirmiran, P.; Wagner, C.L.; Shab-Bidar, S. Vitamin D supplementation and body fat mass: A systematic review and meta-analysis. *Eur. J. Clin. Nutr.* 2018, 72, 1345–1357. [CrossRef]

30. Pathak, K.; Soares, M.J.; Calton, E.K.; Zhao, Y.; Hallett, J. Vitamin D supplementation and body weight status: A systematic review and meta-analysis of randomized controlled trials. *Obes. Rev.* 2014, 15, 528–537. [CrossRef] [PubMed]

31. Heymsfield, S.B.; Wang, Z.; Baumgartner, R.N.; Ross, R. Human body composition: Advances in models and methods. *Annu. Rev. Nutr.* 1997, 17, 527–558. [CrossRef] [PubMed]

32. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur. J. Cancer* 2009, 45, 228–247. [CrossRef] [PubMed]

33. Giantonio, B.J.; Catalano, P.J.; Meropol, N.J.; O’Dwyer, P.J.; Mitchell, E.P.; Alberts, S.R.; Schwartz, M.A.; Benson, A.B.; 3rd; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. *J. Clin. Oncol.* 2007, 25, 1539–1544. [CrossRef] [PubMed]

34. Shen, W.; Punyanitya, M.; Wang, Z.; Gallagher, D.; St-Onge, M.P.; Albu, J.; Heymsfield, S.B.; Heshka, S. Total body skeletal muscle and adipose tissue volumes: Estimation from a single abdominal cross-sectional image. *J. Appl. Physiol.* (1985) 2004, 97, 2333–2338. [CrossRef]

35. Schweitzer, L.; Geisler, C.; Pourhassan, M.; Braun, W.; Gluer, C.C.; Bosy-Westphal, A.; Muller, M.J. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults? *Am. J. Clin. Nutr.* 2015, 102, 58–65. [CrossRef]

36. Aubrey, J.; Esfandiari, N.; Baracos, V.E.; Buteau, F.A.; Frenette, J.; Putman, C.T.; Mazurak, V.C. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. *Acta Physiol. (Oxf.)* 2014, 210, 489–497. [CrossRef]

37. Babic, A.; Rosenthal, M.H.; Bamlet, W.R.; Takahashi, N.; Sugimoto, M.; Danai, L.V.; Morales-Oyarvide, V.; Khalaf, N.; Dunne, R.F.; Brais, L.K.; et al. Postdiagnosis Loss of Skeletal Muscle, but Not Adipose Tissue, Is Associated with Shorter Survival of Patients with Advanced Pancreatic Cancer. *Cancer Epidemiol. Biomarkers Prev.* 2019, 28, 2062–2069. [CrossRef]

38. Akacha, M.; Bretz, F.; Ruberg, S. Estimands in clinical trials - broadening the perspective. *Stat. Med.* 2017, 36, 5–19. [CrossRef]
39. Marshall, A.; Altman, D.G.; Holder, R.L. Comparison of imputation methods for handling missing covariate data when fitting a Cox proportional hazards model: A resampling study. *BMC Med. Res. Methodol.* 2010, 10, 112. [CrossRef]

40. Fitzmaurice, G.M.; Laird, N.M.; Ware, J.H. *Applied Longitudinal Analysis*; John Wiley & Sons: Hoboken, NJ, USA, 2012.

41. Efron, B.; Tibshirani, R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. *Stat. Sci.* 1986, 1, 54–75. [CrossRef]

42. Vander Weele, T. *Explanation in Causal Inference: Methods for Mediation and Interaction*; Oxford University Press: Oxford, UK, 2015.

43. Brown, J.C.; Caan, B.J.; Prado, C.M.; Weltzien, E.; Xiao, J.; Cespedes Feliciano, E.M.; Kroenke, C.H.; Meyerhardt, J.A. Body Composition and Cardiovascular Events in Patients with Colorectal Cancer: A Population-Based Retrospective Cohort Study. *JAMA Oncol.* 2019, 5, 967–972. [CrossRef] [PubMed]

44. Harrell, F. *Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis*; Springer: Berlin, Germany, 2015.

45. Yuan, C.; Ng, K. Vitamin D supplementation: A potential therapeutic agent for metastatic colorectal cancer. *Br. J. Cancer* 2020. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).